2. Макаров И.В., Галкин Р.А., Прокофьева Н.А. и др. Опыт диагностики и хирургического лечения первичного гиперпаратиреоза. Эндокринная хирургия. 2017;11(2):81–9.

3. Российская ассоциация эндокринологов, Ассоциация эндокринных хирургов. Клинические рекомендации «Первичный гиперпаратиреоз». М., 2020. 110 с. Russian Association of Endocrinologists, Association of Endocrine Surgeons. Clinical guidelines «Primary Hyperparathyroidism». M., 2020. 110 p. (In Russ.)].

4. Khan A.A., et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28(1):1–19. Doi: 10.1007/s00198-016-3716-2.

5. Wermers R.A., et al. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965–1992. Ann Int Med. 1997;126(6):433–40. Doi: 10.7326/0003-4819-126-6-199703150-00003.

6. Мокрышева Н.Г., Мирная С.С., Добрева Е.А. и др. Первичный гиперпаратиреоз в России по данным регистра. Проблемы эндокринологии. 2019;65(5):300–10.

7. Мокрышева Н.Г. Первичный гиперпаратиреоз: современное представление о проблеме. Лечение и профилактика. 2013;2:143–52.

8. Мокрышева Н.Г., Гуляева С.С., Рожинская Л.Я.и др. Тяжелое течение гиперпаратиреоза у пожилых. Клинические наблюдения. Проблемы эндокринологии. 2009;55(1):33–5.

9. Castellano E., Tassone F., Attanasio R., et al. Mild primary hyperparathyroidism as defined in the Italian Society of Endocrinology’s Consensus Statement: prevalence and clinical features. J Endocrinol Invest. 2016;39(3):349–54. Doi: 10.1007/s40618-015-0412-6.

10. Bollerslev J., Marcocci C., Sosa M., et al. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol. 2011;165(6):851–64. Doi: 10.1530/EJE-11-0589.

11. Silverberg S.J., Bilezikian J.P. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81(6):2036–40. Doi: 10.1210/jcem.81.6.8964825.

12. Allerheiligen D.A., Schoeber J., Houston R.E. et al. Hyperparathyroidism. Am Fam Physician. 1998;57(8):1795–802.

13. AACE/AAES Task force on primary hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005;11(1):49–54. Doi: 10.4158/EP.11.1.49.

14. Potts J.T., Ackerman I.P., Barker C.F., et al. Diagnosis and management of asymptomatic primary hyperparathyroidism. National Institutes of Health Consensus Development Conference. October 29–31, 1990. Consens Statement.1990;8(7):1–18.

15. Bilezikian J.P., Potts J.T., Fuleihan Gel-H., et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st Century. J Clin Endocrinol Metab. 2002;87(12):5353–61. doi: 10.1210/jc.2002-021370. Problems of Endocrinology. 2019. Article in Press. Doi: 10.14341/probl10126.

16. Eastell R., Arnold A., Brandi M.L., et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):340–50. Doi: 10.1210/jc.2008-1758.

17. Bilezikian J.P., Brandi M.L., Eastell R., et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561–69. Doi: 10.1210/jc.2014-1413.

18. Yeh M.W., Ituarte P.H., Zhou H.C., et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122–29. Doi: 10.1210/jc.2012-4022.

19. Yu N., Donnan P.T., Murphy M.J., Leese G.P. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf). 2009;71(4):485–93. Doi: 10.1111/j.1365-2265.2008.03520.x.

20. Мокрышева Н.Г. Первичный гиперпаратиреоз: эпидемиология, клиника, современные принципы диагностики и лечения.

21. Saliba W., Barnett O., Rennert H.S., et al. The Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels. Am J Med. 2011;124(12):1165–70. Doi: 10.1016/j.amjmed.2011.07.009.

22. Heaney R.P. The vitamin D requirement in health and disease. J Steroid Biochem Mol. Biol. 2005;97:13–9. Doi: 10.1016/j.jsbmb.2005.06.020.

23. Holick M.F. Vitamin D deficiency. N Eng J Med. 2007;357:266–81. Doi: 10.1056/NEJMra070553.

24. Monchik J.M., Gorgun E. Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery. 2004;136(6):1242–46. Doi: 10.1016/j.surg.2004.06.052.

25. Lowe H., et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8):3001–5. Doi: 10.1210/jc.2006-2802.

26. Silverberg S.J., Bilezikian J.P. “Incipient” primary hyperparathyroidism: a ”forme fruste” of an old disease. J Clin Endocrinol Metab. 2003;88(11):5348–52. Doi: 10.1210/jc.2003-031014.

27. Christensen S.E., et al. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol. 2008;69(5):713–20. Doi: 10.1111/j.1365-2265.2008.03259.x.

28. Nordenstrom E., Katzman P., Bergenfelz A. Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem. 2011;44(10–11):849–52. Doi: 10.1016/j.clinbiochem.2011.04.002.

29. Amin A.L., et al. Normal PTH levels in primary hyperparathyroidism: still the same disease? Ann Surg Oncol. 2011;18(12):3437–42. Doi: 10.1245/s10434-011-1744-x.